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Cre/lox-assisted non-invasive in vivo tracking of
specific cell populations by positron emission
tomography
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Many pathophysiological processes are associated with proliferation, migration or death of
distinct cell populations. Monitoring specific cell types and their progeny in a non-invasive,
longitudinal and quantitative manner is still challenging. Here we show a novel cell-tracking
system that combines Cre/lox-assisted cell fate mapping with a thymidine kinase (sr39tk)
reporter gene for cell detection by positron emission tomography (PET). We generate
Rosa26-mT/sr39tk PET reporter mice and induce sr39tk expression in platelets, T lympho-
cytes or cardiomyocytes. As proof of concept, we demonstrate that our mouse model permits
longitudinal PET imaging and quantification of T-cell homing during inflammation and
cardiomyocyte viability after myocardial infarction. Moreover, Rosa26-mT/sr39tk mice are
useful for whole-body characterization of transgenic Cre mice and to detect previously
unknown Cre activity. We anticipate that the Cre-switchable PET reporter mice will be
broadly applicable for non-invasive long-term tracking of selected cell populations in vivo.
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Tracking cells non-invasively in vivo by molecular imagingallows the observation of cell behavior in health anddisease1. In addition to its importance for basic research,
cell tracking has many potential applications in regenerative and
individualized medicine and it facilitates the development of new
diagnostic tools and therapeutic strategies2–5. Numerous imaging
techniques are used to visualize cells in vivo, including
ultrasound, optical imaging, magnetic resonance imaging (MRI)
and positron emission tomography (PET). These methods require
conceptually different labeling and detection strategies that each
have inherent advantages and disadvantages. Direct cell labeling
makes use of radioactive, fluorescent or paramagnetic
compounds, which are, however, eventually washed out and get
diluted. Thus, longitudinal and quantitative monitoring of cells
becomes challenging. In contrast, strategies based on stable
expression of a chromosomally integrated reporter transgene
permit long-term labeling of cells and their progeny1.
The Cre/lox recombination system has emerged as a powerful
tool to generate time- and tissue-specific mouse mutants6, 7. In
addition, this technology can be used to genetically label specific
cell populations to map their fate during development8 or in
adult mice in the context of physiological or pathophysiological
processes9. For genetically inducible fate mapping, cell type-
specific expression of the tamoxifen-inducible CreERT2 recom-
binase is combined with Cre-activatable reporter transgenes that
are driven by ubiquitous promoters. With this approach, stable,
inheritable reporter gene expression can be achieved in a distinct
cell population labeled by Cre recombination at a predetermined
time. Cre reporter transgenes encoding histochemical, fluorescent
or bioluminescent reporter proteins have been integrated into the
murine Rosa26 (R26) locus, which is accessible to the transcrip-
tional machinery in most if not all cell types10. With the currently
available R26 Cre reporter mouse lines, however, non-invasive
quantitative detection of labeled cells in vivo at the whole-body
level is not possible, because detection of the aforementioned
reporter proteins relies on either ex vivo methods requiring tissue
fixation, invasive methods with a small field of view such as
intravital microscopy, or semi-quantitative non-invasive methods
such as bioluminescence imaging.
PET is a powerful non-invasive imaging modality in both
preclinical and clinical settings. It has a high sensitivity and
generates quantitative data, and recent advances in PET-MRI
scanner technology enable simultaneous acquisition of functional
and morphological information from living mice11. Reporter
genes for detection of cells by PET cause the accumulation of
radiolabeled probes on or in reporter gene-expressing cells12, 13.
One such PET reporter gene is the herpes simplex virus type 1
thymidine kinase (HSV1-tk). It is used in combination with
18F- or 124I-labeled nucleoside analogues, which are phosphory-
lated by HSV1-tk, but not by mammalian thymidine kinases. In
their non-phosphorylated form, PET tracers such as 9-(4[18F]-
Fluoro-3-[hydroxymethyl]butyl)guanine are “cell-permeable”,
but after phosphorylation by HSV1-tk they are retained inside the
cells. HSV1-tk or an improved variant that enables PET with
higher sensitivity, sr39tk14, 15, have been used for PET imaging of
rodents, larger animals and humans12, 13. Cre-mediated activa-
tion of HSV1-tk expression has been achieved via the delivery of
an adenovirus carrying a Cre-activatable HSV1-tk construct to
the liver16 or myocardium17 of mice expressing Cre in the
respective target tissues. However, transgenic mice with a chro-
mosomally integrated Cre-responsive PET reporter gene have not
been described to date. In such a mouse line, Cre-expressing
cell populations will be labeled for PET imaging through
Cre-mediated activation of reporter gene expression at the
genomic level. Once reporter gene expression is activated, cells
and their progeny are stably labeled, even if the cells proliferate or
change their phenotype, which may lead to a loss of Cre
expression. This approach would permit non-invasive long-term
visualization of any given cell population for which a respective
cell type-specific Cre mouse line is available.
To improve cell tracking in mammals, we generated R26 knock-
in mice carrying a transgene for Cre-inducible sr39tk expression
under control of the ubiquitous cytomegalovirus early enhancer/
chicken β-actin/β-globin (CAG) promoter. As these mice express
membrane-targeted tandem-dimer tomato red fluorescent protein
(mT) before Cre recombination and sr39tk after Cre recombina-
tion, we named them “R26-mT/sr39tk” mice. In these mice, a cell
population of interest is labeled by Cre-dependent activation of
sr39tk expression and then the fate of these cells is followed by
non-invasive PET imaging with [18F]FHBG. As proof of concept,
we demonstrate that the new R26-mT/sr39tk reporter mice enable
cell type-specific longitudinal PET imaging of T-cell homing
during tissue inflammation and of cardiomyocytes after
myocardial infarction (MI). Furthermore, the Cre-responsive PET
reporter allele permits non-invasive whole-body characterization
of transgenic Cre mouse lines.
Results
Generation of R26-mT/sr39tk mice. We integrated the R26-mT/
sr39tk PET reporter construct by homologous recombination into
the R26 locus of murine embryonic stem (ES) cells. Before Cre
recombination, mT is expressed from the L2 allele, where “L2”
stands for “two loxP sites”. In Cre-expressing cells, Cre recombinase
removes the mT-encoding expression cassette and thereby activates
sr39tk expression from the resulting L1 allele (“L1” stands for one
loxP site) (Fig. 1 and Supplementary Fig. 1a). Cre-mediated activa-
tion of sr39tk expression in ES cells was confirmed at multiple levels:
at the DNA level by Southern blot analysis (Supplementary Fig. 1b),
at the protein level by western blot analysis (Supplementary Fig. 1c),
and at the functional level by testing the sensitivity of the cells to the
sr39tk suicide substrate ganciclovir (Supplementary Fig. 1d), as well
as by measuring uptake of the PET tracer [18F]FHBG into the cells
(Supplementary Fig. 1e). ES cells carrying the Cre-responsive L2
allele were used to establish the R26-mT/sr39tk mouse line. In line
with previous publications18, 19, which used the same targeting
vector but different reporter genes, we observed strong and
ubiquitous mT expression in organs isolated from R26-mT/sr39tk
mice (Supplementary Fig. 1f). The general appearance and viability
of R26-mT/sr39tk mice (genotype: R26[sr39tk/+], where “+” denotes
the wild-type allele) was normal. However, male R26-mT/sr39tk
mice showed severely reduced fertility. Male infertility has been
described for some other HSV1-tk transgenic mouse lines and is
presumably caused by HSV1-tk expression from a cryptic promotor
located in the HSV1-tk coding region that is active in postmeiotic
germ cells leading to impaired sperm development20, 21. Therefore,
female R26-mT/sr39tk mice, which showed normal fertility and
litter sizes, were used to maintain the R26-mT/sr39tk line and for
crossbreeding with transgenic Cre mice.
Detection of sr39tk-expressing cell populations by PET.
We mated R26-mT/sr39tk mice with Pf4-Cre22, CD4-Cre23 or
Myh6-Cre24 mice with Cre[tg/+] genotype (where ‘+‘ denotes the
wild-type allele) to induce expression of sr39tk in platelets, T
lymphocytes or cardiomyocytes, respectively (Fig. 1a and Supple-
mentary Table 1). Animals carrying tissue-specific Cre and R26-mT/
sr39tk transgenes are denoted “Cre promoter/sr39tk” mice. We
performed in vivo [18F]FHBG-PET imaging studies (Fig. 2) with
Cre-positive experimental mice that were expected to express sr39tk
in the respective target cells (sr39tk+; genotype: Cre[tg/+],
R26[sr39tk/+]). To evaluate nonspecific tracer uptake, Cre-negative
control animals (sr39tk−; genotype: Cre[+/+],R26[sr39tk/+]) were
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analyzed in parallel. To allocate PET signals to anatomical structures,
some animals underwent MRI. In addition to in vivo imaging,
[18F]FHBG uptake was assessed ex vivo via autoradiography and
biodistribution analysis of selected organs (Fig. 3). To validate results
obtained with R26-mT/sr39tk PET reporter mice, we tested all Cre
transgenes with the well-established R26-lacZ Cre reporter line10.
LacZ-expressing mice (lacZ+; genotype: Cre[tg/+],R26[lacZ/+]) are
denoted “Cre promoter/lacZ” mice. These mice were used to detect
Cre-mediated activation of β-galactosidase expression by 5-bromo-
4-chloro-3-indolyl-β-D-galactoside (X-Gal) staining of fixed tissues.
Cre-negative mice (lacZ−; genotype: Cre[+/+],R26[lacZ/+])
were used as negative controls for X-Gal staining (Supplementary
Fig. 2 and 3).
In Pf4/sr39tk mice for visualization of platelets, we observed
strong [18F]FHBG accumulation in the spleen and weaker but still
significant tracer uptake in lung and skeletal muscle (Fig. 2a, d
left). Ex vivo analyses confirmed significant tracer accumulation
in spleen, lungs and skeletal muscle, and, in addition,
revealed sr39tk reporter gene activity in bone marrow and blood
(Fig. 3a, d). The activity of the Pf4-Cre transgene in cells of bone
marrow, blood and spleen was also demonstrated by detection of
β-galactosidase-positive cells in Pf4/lacZ mice (Supplementary
Fig. 2a–c). Together, these results indicated that the PET signals
observed in organs of Pf4/sr39tk mice, including signals in lung
and skeletal muscle, were indeed derived from megakaryocytes
and blood-borne platelets. In agreement with previous reports,
nonspecific accumulation of background radioactivity was
observed in the gastrointestinal tract25 as well as in bone26 of
sr39tk+and sr39tk− animals (Fig. 2a–c).
CD4/sr39tk mice for T-cell tracking studies showed specific
[18F]FHBG uptake in the spleen, lymph nodes and thymus, and,
unexpectedly, in the heart and lung (Figs. 2b, d middle and 3b, e).
The PET signal observed in the spleen of CD4/sr39tk mice was
significantly stronger than in sr39tk− control mice, but weaker than
in Pf4/sr39tk mice (Figs 2d and 3d, e). In line with these results,
CD4/lacZ mice demonstrated β-galactosidase activity in lymphatic
organs (Supplementary Fig. 2d–f) as well as in heart and lung
(Supplementary Fig. 2g, h). Closer inspection of X-Gal-stained
tissue sections and immunostaining of marker proteins indicated
previously unknown ectopic activity of the CD4-Cre transgene in
smooth muscle cells of medium-caliber vessels of the heart
(Supplementary Fig. 3a, b) as well as in bronchial epithelial cells
of the lung and alveolar macrophages (Supplementary Fig. 3c–f).
Ectopic activity of the CD4-Cre line in some vascular smooth
muscle cells could also explain the weak but significant tracer





























































Fig. 1 Strategy for PET-based cell tracking with the R26-mT/sr39tk mouse line. a Generation of experimental animals for PET imaging. R26-mT/sr39tk
mice carry the Cre-activatable R26-mT/sr39tk transgene that has been integrated via homologous recombination into the Rosa26 (R26) locus. In
R26-mT/sr39tk mice, sr39tk expression is blocked by a loxP-flanked (triangles) gene cassette encoding membrane-targeted tandem dimer tomato red
fluorescent protein (mT). R26-mT/sr39tk mice are mated with mice that express Cre (or CreERT2) under control of a cell type-specific promoter (e.g., Pf4,
CD4 or Myh6). In progeny mice, Cre recombination activates sr39tk expression in the respective target cell population (blue shaded oval) as shown in
detail in b. b Strategy for Cre-dependent sr39tk expression and labeling of distinct cell types. The R26-mT/sr39tk L2 allele (carrying two loxP sites)
encodes sr39tk preceded by a loxP-flanked (triangles) sequence encoding the mT protein. From the L2 allele, mT but not sr39tk is expressed. In cells
expressing Cre recombinase, the mT cassette is removed and thereby the L2 allele is converted to the L1 allele (carrying one loxP site), from which sr39tk
is expressed under control of the ubiquitous CAG promoter. Sr39tk phosphorylates the tracer molecule [18F]FHBG, which cannot leave the cell once
phosphorylated. [18F]FHBG accumulation in sr39tk-expressing cell populations allows their in vivo detection by PET imaging. See also Supplementary Fig. 1
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In Myh6/sr39tk mice for detection of cardiomyocytes, in vivo
PET imaging (Fig. 2c, d right) as well as ex vivo analysis of tissues
(Fig. 3c, f) revealed strong [18F]FHBG uptake in the heart and, to a
much smaller extent, in the lungs. These results were confirmed in
Myh6/lacZ mice, which showed β-galactosidase activity in
cardiomyocytes (Supplementary Fig. 2i) as well as in pulmonary
vascular smooth muscle cells (Supplementary Figs. 2j and 3g, h).
We also explored whether sr39tk expression exerted effects on
the respective target cells. The general appearance and viability of
Cre/sr39tk mice (genotype: Cre[tg/+],R26[sr39tk/+]) analyzed in
this study was normal. In Pf4/sr39tk mice, platelet counts in
peripheral blood were not significantly different from control
mice (Supplementary Fig. 4a). In naive CD4/sr39tk mice
(genotype: Cre[tg/+],R26[sr39tk/+]), we determined T-cell
numbers in the lymph nodes, spleen and thymus by flow
cytometry. Compared with wild-type mice (genotype: Cre[+/+],
R26[+/+]), CD4/sr39tk mice had a smaller number of CD3+
lymphocytes, which was primarily due to a smaller fraction of
CD4+ T cells (Supplementary Fig. 4b–d). It has been reported that
CD4-Cre mice have reduced T-cell numbers, particularly CD4+
T cells in the spleen27. However, the CD4-Cre mice (genotype:
Cre[tg/+],R26[+/+]) used in our studies showed T-cell numbers
similar to wild-type mice, except for a slightly lower number of
CD8+ T cells in the thymus that was statistically significant
(Supplementary Fig. 4b–d). Thus, the reduced number of T cells
we observed in CD4/sr39tk mice was apparently mainly caused
by expression of sr39tk and not by expression of Cre
recombinase. The spleen weight of CD4/sr39tk mice was not
altered compared with control mice (Supplementary Fig. 4e).
Taken together, these results indicated that the R26-mT/sr39tk
mouse line is useful to label a broad spectrum of cell types via
crossbreeding to existing tissue-specific Cre lines. Importantly, the
expression of the sr39tk reporter gene after Cre-mediated activation



































































































Fig. 2 In vivo analysis of [18F]FHBG uptake in mice with different sr39tk-expression profiles. Panels show representative [18F]FHBG-PET images of sr39tk-
expressing mice (sr39tk+; genotype: Cre[tg/+],R26[sr39tk/+]) and Cre-negative control animals (sr39tk−; genotype: Cre[+/+],R26[sr39tk/+]); ‘+’
denotes the wild-type allele. To confirm uptake into distinct anatomic locations, MR images were recorded and overlaid with PET images (PET/MRI).
Nonspecific signals that were observed in both sr39tk+ and sr39tk− animals originate from the bone (*) and gastrointestinal tract (#). Specific tracer
uptake was detected in a Pf4/sr39tk mice (Pf4-Cre) in the spleen (S), lung (L) and skeletal muscle (see also d left); b CD4/sr39tk mice (CD4-Cre) in
the spleen (S), heart (H) and lung (L) (see also d middle); c Myh6/sr39tk mice (Myh6-Cre) in the heart (H) and lung (see also d right). PET images of
sr39tk+ mice and sr39tk− control animals were normalized to injected tracer dose. Pictograms on the left show orientation and relative position of
the image plane (red). d [18F]FHBG uptake was quantified from manually drawn regions of interest (ROIs) in selected organs of four Pf4/sr39tk and six
sr39tk−mice (left), four CD4/sr39tk and six sr39tk−mice (middle), and four Myh6/sr39tk and six sr39tk−mice (right) (SkM, skeletal muscle). Data points
represent individual animals. Tracer uptake was normalized to injected tracer dose (ID) and ROI volume (in c.c.m.). Insets for skeletal muscle (Pf4-Cre) and
lung (Myh6-Cre) show [18F]FHBG uptake between 0 and 1 %ID per c.c.m. One-way ANOVA was performed to compare tracer uptake into organs of
sr39tk+ and sr39tk− animals **p< 0.01 and ***p< 0.001, respectively). See also accompanying ex vivo analysis of [18F]FHBG uptake in Fig. 3, further
analysis of Cre recombinase activity in Supplementary Figs 2 and 3, and characterization of the effects of sr39tk expression on cell counts in Supplementary
Fig. 4
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population of interest and of previously unknown Cre activity in
other cell types, via non-invasive PET imaging in vivo. Next, we
evaluated the suitability of the R26-mT/sr39tk reporter mouse line for
longitudinal cell tracking in two clinically relevant disease models.
T-cell homing during inflammation. To monitor T-cell homing
during inflammation, we used a mouse model of allergic contact
dermatitis, one of the most frequent inflammatory skin diseases.
It is characterized by a T-cell-mediated hypersensitivity reaction
of the skin and also studied as a paradigm for autoimmune
disorders, antiviral and antitumor immunity28. A cutaneous
delayed-type hypersensitivity reaction (DTHR) was induced in
CD4/sr39tk (sr39tk+) mice and, as a control for nonspecific tracer
uptake, in Cre-negative mice (sr39tk−). In our animal model29,
mice were first sensitized at the abdomen by application of
2,4,6-trinitrochlorobenzene (TNCB) at day 0. Then, we elicited a
cutaneous DTHR on the left ear by repetitive application of
TNCB on day 7, 10 and 12, and used [18F]FHBG-PET to follow
homing of sr39tk-expressing T lymphocytes to the left ear. PET
imaging was performed on day 6 (1 day before the first TNCB
challenge), on day 13 (1 day after the last TNCB challenge) and
on day 20 (Fig. 4a). The degree of inflammation was determined
by measuring ear thickness before and after TNCB ear challenges
(Supplementary Fig. 5a). On day 13, 12 h after the last TNCB ear
challenge, PET imaging of the animals revealed strong
accumulation of [18F]FHBG in the challenged left ear, but not in
the non-challenged right ear of sr39tk+ mice or in ears of sr39tk−
control animals (Fig. 4b). Compared with baseline on day 6, [18F]
FHBG uptake into the TNCB-challenged left ears of sr39tk+ mice
was ≈6-fold higher in each animal on day 13 and then returned
to a lower level on day 20 (Fig. 4b right), in line with
reduced inflammation and ear thickness 8 days after the
third TNCB- challenge (Supplementary Fig. 5a). In contrast,
[18F]FHBG uptake into the non-challenged right ears of sr39tk+
mice or into the ears of sr39tk− animals remained at a low level
over the entire time course (Fig. 4b right). PET imaging of the
spleen, lung and liver did not show significant changes in tracer
uptake over time in these organs, indicating the absence of a
strong systemic immune response in the experimental animals
(Supplementary Fig. 5b–d). Autoradiography of the ears on day
20 confirmed strong [18F]FHBG uptake into the TNCB-
challenged left ears of sr39tk+ mice (Fig. 4c). Autoradiography
detected elevated tracer uptake also in the non-challenged right
ears of sr39tk+ mice, in particular in one of the three sr39tk+
animals analyzed (Fig. 4c). This was likely due to scratching and
transfer of TNCB from the left to the right ear, thereby, inducing
inflammation also in the “non-challenged” right ear. The data
obtained in vivo by PET imaging and ex vivo by autoradiography
showed a good correlation (Supplementary Fig. 5e). We can






















































































































Fig. 3 Ex vivo analysis of [18F]FHBG uptake in mice with different sr39tk expression profiles. a–c Representative [18F]FHBG autoradiographs from various
organs of (a) Pf4/sr39tk (Pf4-Cre), (b) CD4/sr39tk (CD4-Cre) and (c) Myh6/sr39tk (Myh6-Cre) mice. sr39tk-expressing mice (sr39tk+; genotype:
Cre[tg/+],R26[sr39tk/+]) were compared with Cre-negative control mice (sr39tk−; genotype: Cre[+/+],R26[sr39tk/+]); ‘+’ denotes the wild-type allele.
Twenty-micrometer cryosections were used except for lymph nodes (b), which were not cut before autoradiography. Autoradiographs of the same organs
from sr39tk+ and sr39tk− mice were derived from the same phosphor screen, but they were not normalized between organs or Cre lines. Organs were not
cleared from blood before analysis. Similar results were obtained with organs from ≥3 animals of each genotype. d–f Biodistribution analysis of [18F]FHBG
uptake into organs isolated from (d) Pf4/sr39tk (Pf4-Cre), (e) CD4/sr39tk (CD4-Cre) and (f) Myh6/sr39tk (Myh6-Cre) mice with (sr39tk+, black
symbols) or without (sr39tk−, open symbols) expression of sr39tk. Uptake was normalized to injected tracer dose (ID) and tissue weight, except for bone
marrow (BM, d), which was flushed from one tibia and femur per mouse with 1 mL PBS. Data points represent individual animals. Inset for skeletal muscle
in d shows uptake between 0 and 0.2 %ID per g tissue and insets for skeletal muscle in e and lung in f show [18F]FHBG uptake between 0 and 0.5 %ID per
g tissue. One-way ANOVA was used to compare [18F]FHBG uptake into organs of sr39tk+ and sr39tk− animals (**p< 0.01 and ***p< 0.001, respectively).
Organs were not cleared from blood before analysis. BM, bone marrow; SkM, skeletal muscle
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challenged ears of sr39tk+ mice was the consequence of
inflammation-induced increases in perfusion or vascular perme-
ability (Supplementary Fig. 5a) as we observed no [18F]FHBG
uptake in repetitively TNCB-challenged and, thus, strongly
inflamed ears of Cre−, sr39tk− control animals (Fig. 4b, c). In
sum, our data obtained with CD4/sr39tk mice in the DTHR
inflammation model demonstrated that the novel PET reporter
transgene allows non-invasive in vivo tracking of endogenous
T cells longitudinally over several weeks in mice.
Cardiomyocyte viability after MI. As a second clinically relevant
disease model, we performed longitudinal PET imaging of
cardiomyocytes after MI in Myh6i/sr39tk mice. Myh6i mice
express the tamoxifen-inducible CreERT2 recombinase under
control of the cardiomyocyte-specific Myh6 promoter30. To
activate sr39tk expression specifically in cardiomyocytes of adult
mice, 17-week-old mice received 1 mg tamoxifen per day for
5 days by intraperitoneal injection. Four weeks later, MI was
induced by 60 min temporary ligation (ischemia/reperfusion, I/R
group) or permanent ligation (Lig group) of the left anterior
descending coronary artery (LAD). Control animals underwent
surgery without LAD ligation (Sham group). The study protocol
is depicted in Fig. 5a. In week 1, 2 and 3 after MI, we performed
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Fig. 4 Longitudinal tracking of T-cell homing in CD4/sr39tk mice during cutaneous DTHR. a At day 0 (d0), four CD4/sr39tk mice (sr39tk+; genotype:
CD4-Cre[tg/+],R26[sr39tk/+]) and three litter-matched Cre-negative control animals (sr39tk−; genotype: CD4-Cre[+/+],R26[sr39tk/+]) were
sensitized by cutaneous application of 5% TNCB to the abdomen (red arrow at day d0). Cutaneous DTHR on the left ear was elicited by three repetitive
challenges with 1% TNCB on day 7, 10, 12 (red arrows). Animals were analyzed by [18F]FHBG-PET on day 6, 13 and 20, and killed on day 20 for ex vivo
analysis of [18F]FHBG uptake. One sr39tk+ animal developed an infection of the TNCB-challenged ear and was excluded from analysis. One sr39tk− animal
died on day 20. b Left, representative [18F]FHBG-PET images of the head region of a sr39tk+ and a sr39tk− mouse recorded on day 13. Ear boundaries are
outlined by dashed lines; left ears had been challenged with TNCB, whereas right ears had not been challenged (Ctrl). Images were normalized to injected
tracer dose. Pictograms on the left show orientation and relative position of the image plane (red). Nonspecific tracer accumulation was detected in bone
(*). Right, longitudinal PET imaging showing the time course of [18F]FHBG uptake into TNCB-challenged ears (TNCB, black symbols) and non-challenged
ears (Ctrl, white symbols) of individual sr39tk+ (left) and sr39tk− (right) mice. Values were normalized to injected tracer dose (ID); grey dashed lines
represent 0% ID for each animal. c Left, [18F]FHBG autoradiography of the ears from three sr39tk+ and two sr39tk−mice at the end of the study on day 20;
left ears had been challenged with TNCB; right ears had not been challenged (Ctrl). Right, quantification of [18F]FHBG uptake by autoradiography of the
TNCB-challenged ears (TNCB, black symbols) and non-challenged ears (Ctrl, white symbols). Intensity (arbitrary units, a.u.) was background-corrected and
normalized to injected tracer dose (ID); data points indicate individual animals; bars represent mean± s.e.m. See also Supplementary Fig. 5
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-00482-y
6 NATURE COMMUNICATIONS |8:  444 |DOI: 10.1038/s41467-017-00482-y |www.nature.com/naturecommunications
the same animals, glucose uptake into the heart was detected by
2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG)-PET imaging in
week 1 and 2 after MI. To suppress [18F]FDG uptake into
cardiomyocytes and allow imaging of post-infarct inflammation,
we used ketamine and xylazine for anesthesia. With this protocol
it is possible to preferentially detect non-cardiomyocytes that take
up [18F]FDG, such as immune cells (neutrophils, macrophages,
etc.) known to accumulate in the post-ischemic myocardium31, 32.
To analyze regional differences in tracer uptake in sham-operated
and infarcted hearts, we created polar maps (PMs) of the left
ventricle. Representative PET images and corresponding PMs are
shown in Fig. 5b (for an extended presentation of PET data, see
Supplementary Fig. 6). As expected, sham-operated Myh6i/sr39tk
mice showed strong and uniform [18F]FHBG uptake into the
myocardium, whereas [18F]FDG uptake was low (Fig. 5b upper).
Infarcted hearts of the I/R group (Fig. 5b middle) and Lig group
(Fig. 5b lower) could be well imaged by detection of viable car-
diomyocytes with [18F]FHBG-PET, with the respective infarcted
area spared. [18F]FHBG-PET signals appeared stable over the
whole time course of ≈3 weeks after MI. Compared with remote
myocardium, [18F]FDG uptake into the infarct zone appeared to
be increased after MI, presumably due to uptake by infiltrating
immune cells. In contrast to the results with [18F]FHBG-PET the
[18F]FDG-PET signals in infarcted hearts appeared to be more
variable over time, and in mice of the I/R group [18F]FDG uptake
was clearly present in the infarcted regions spared by [18F]FHBG
(Fig. 5b).
Quantification of tracer uptake into individual segments of the
left ventricle confirmed differences between [18F]FHBG-PET and
[18F]FDG-PET signals (for an illustration of the segmentation
model, see Supplementary Fig. 7a). The infarcted area was defined
as segments with a reduction of [18F]FHBG uptake to <50% of
maximal uptake in the same heart. The number of infarcted
segments was similar in the I/R group and the Lig group
(Supplementary Fig. 7b). Uptake of [18F]FHBG into the whole left
ventricle (infarcted and non-infarcted segments) as well as into
the infarcted area alone was stable over 18 days after MI
(Supplementary Fig. 7c left, d left). In contrast, uptake of
[18F]FDG into the whole left ventricle as well as infarcted area
was higher at 5 days than at 14 days after MI, particularly in the I/
R group (Supplementary Fig. 7c right, d right). In both the I/R
and Lig group, [18F]FHBG uptake into the infarcted area was
consistently reduced by 50–60% compared to the non-infarcted
area of the left ventricle (Supplementary Fig. 7e left). [18F]FDG
uptake into infarcted areas in the Lig group was reduced by
≈25%, whereas infarcted areas from mice in the I/R group
showed similar or even slightly higher [18F]FDG uptake than
non-infarcted myocardium (Supplementary Fig. 7e right). Some
Myh6i/sr39tk animals in this study also carried the R26-lacZ Cre




































































Fig. 5 Longitudinal [18F]FHBG and [18F]FDG PET study in Myh6i/sr39tk mice
with myocardial infarction (MI). a Expression of sr39tk was induced in
cardiomyocytes of 11 Myh6i/sr39tk mice (genotype: Myh6i-Cre[tg/+],
R26[sr39tk/+]) by intraperitoneal injection of 1 mg tamoxifen for 5
consecutive days starting 4 weeks before surgery. MI was caused on day 1
(d1) by 60-min temporary ligation (ischemia/reperfusion, I/R) or on day 2 by
permanent ligation (Lig) of the left anterior descending coronary artery in
three to five animals per group. Two animals underwent surgery without
ligation (Sham). All mice underwent [18F]FHBG-PET on day 4, 13 and 18, and
[18F]FDG-PET on day 5 and 14. b Representative PET images of the heart
(HLA, horizontal long axis; SA, short axis; VLA, vertical long axis) and
corresponding polar maps (PMs) of the left ventricle of individual mice over
the time course of the study (for an extended presentation of PET images, see
Supplementary Fig. 6). PMs provide an overview of myocardial tracer uptake
and were segmented for further regional quantification (see Supplementary
Fig. 7). Nonspecific signals were derived from bone (*). PET images were
normalized to injected dose of the respective tracer, PMs were normalized to
maximal tracer uptake for each tracer, animal and image acquisition. c Some
Myh6i/sr39tk mice of this study carried also the R26-lacZ Cre reporter
transgene. A representative example of a mouse with permanent ligation is
shown. After in vivo [18F]FHBG-PET imaging (left, nonspecific signals from
bone are indicated by *) and autoradiography of a 20-µm short-axial
cryosection of the heart (middle) on day 18, β-galactosidase activity was
detected in the same section via X-Gal staining (right, counterstain with
hematoxylin and eosin). Red outlines demonstrate the correlation between loss
of [18F]FHBG uptake and loss of β-galactosidase activity in the infarcted
region (open arrowheads). High-magnification image shows the border region
between healthy and infarcted tissue at single-cell resolution (enlarged from
overview picture; scale bar: 250 µm). See also Supplementary Figs 6 and 7
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[18F]FHBG-PET imaging and ex vivo [18F]FHBG-autoradiogra-
phy with β-galactosidase activity in identical heart sections. We
observed that loss of [18F]FHBG uptake correlated well with loss
of β-galactosidase activity (Fig. 5c). In sum, these experiments
showed the feasibility of longitudinal [18F]FHBG-PET imaging
using our cardiomyocyte-specific sr39tk reporter mice to monitor
cardiomyocyte viability after MI and to characterize infarcts in
detail, particularly when [18F]FHBG- and [18F]FDG-PET are
combined to image cardiomyocytes and immune cells,
respectively.
Discussion
In this study, we have established a modular Cre/lox-based
system for non-invasive labeling, tracking and quantification of
distinct cell populations in mice. This system relies on stable
expression of the sr39tk PET reporter in the cells of interest as
well as their progeny. In addition to enabling in vivo cell tracking
at the whole-body level, our approach has several advantages over
cell-tracking methods that are based on direct cell labeling or
expression of a reporter transgene driven by a cell-type-specific
promoter. As the sr39tk transgene is integrated into the genome,
it permits stable cell labeling that is passed on to all progeny cells.
Initially, expression of sr39tk is silenced, but it can be activated
in the cell type of interest by crossbreeding with an appropriate
cell-type-specific Cre mouse line. Once activated, sr39tk expres-
sion is driven by the ubiquitous CAG promoter, rendering it
independent of subsequent changes of cell differentiation and
potential silencing of tissue-specific promoters. Furthermore, no
ex vivo labeling procedures are required, i.e., the cell population
of interest is labeled in situ in its physiological environment.
As a proof of concept, we labeled and visualized various cell
types by PET imaging and we validated our new mouse model for
longitudinal non-invasive cell tracking in two clinically relevant
disease models. In Pf4/sr39tk, CD4/sr39tk or Myh6/sr39tk mice,
we were able to detect platelets, T cells or cardiomyocytes,
respectively, by [18F]FHBG-PET imaging in vivo. In general,
expression of sr39tk did not cause gross abnormalities in the
number and/or function of the target cells. We noted that the
number of CD4+ T cells was reduced in CD4/sr39tk mice as
compared with control mice, but the TNCB-specific response of
sr39tk-expressing T cells in the context of our DTHR model was
apparently not compromised, as the extent of ear swelling in
CD4/sr39tk mice was similar to control mice not expressing
sr39tk. The reason for the lower T-cell number in CD4/sr39tk
mice is not clear. It is unlikely that it was caused by the potential
immunogenicity of the sr39tk protein33, because CD4/sr39tk
mice express the protein permanently and should, therefore, not
mount an immune response against it.
Platelets, T cells and cardiomyocytes could be visualized in vivo
in anesthetized mice and specific [18F]FHBG uptake in these cells
was confirmed by ex vivo analyses. In few cases, in vivo detection
of the respective target cells was compromised by nonspecific
accumulation of radioactivity and/or unexpected Cre activity in
some tissues. For instance, it was difficult to detect T cells in
distinct lymph nodes and the thymus of CD4/sr39tk mice in vivo.
Visualization of lymph nodes was impeded by background
radioactivity in the bone and gastrointestinal tract, whereas the
thymus was masked by [18F]FHBG accumulation in the heart and
lungs. The latter was due to previously unknown activity of the
CD4-Cre transgene in non-lymphocyte cells of heart and lung.
The problem of ectopic Cre activity can be solved by using Cre
lines with alternative promoters to drive Cre expression. The
current limitation in quantifying T cells in lymph nodes could be
overcome by increasing the purity of the [18F]FHBG preparation,
which was 82–92% in the present study, thereby reducing the
amount of free [18F]fluoride, which accumulates in the bone.
Background radioactivity in the gastrointestinal tract could be
reduced by increasing [18F]FHBG elimination via the intestine or
by using alternative sr39tk substrates with faster clearance such
as [18F]FEAU34, 35. In addition, the use of thymidine kinase
substrates carrying [124I] as longer-lived PET isotope has been
described35, 36. With [124I]-labeled radiotracers, PET imaging
can be performed much later after tracer injection than
with short-lived [18F]-labeled tracers, thereby allowing more
‘non-trapped’ tracer to be eliminated before image acquisition.
Another approach to reduce background signals could be the use
of alternative PET reporter genes such as the human or rat
sodium iodide symporter. However, the respective tracer, iodine,
may show the problem of insufficient intracellular retention due
to iodine efflux37.
Detailed knowledge of the specificity of Cre recombination is
not only important for cell tracking experiments as described in
the present study, but also when Cre mice are used to generate
tissue-specific gene knockouts. Published characterization data for
Cre strains are often limited to a few specific tissues that were
studied in the context of a focused research question. However, it
is increasingly recognized that any given transgenic Cre line may
display recombination activity beyond the intended tissue or cell
type. Therefore, careful characterization of Cre mouse lines is
warranted38. The R26-mT/sr39tk reporter mouse provides the
possibility for recombination profiling of transgenic Cre mice on a
whole-body scale using PET imaging. This novel approach com-
plements existing strategies for comprehensive Cre strain char-
acterization that are based on post-mortem analyses of
conventional LacZ Cre reporter mice (http://www.creportal.org)38.
Indeed, using our sr39tk PET reporter mice for whole-body
imaging combined with the LacZ Cre reporter for subsequent
post-mortem analyses of tissue sections, we have identified several
previously unreported activities of commonly used Cre strains.
Ectopic activity was detected in CD4-Cre mice in smooth muscle
cells of myocardial blood vessels as well as in alveolar macro-
phages and bronchial epithelial cells of the lung, and in Myh6-Cre
mice in the lung vasculature.
Among the most exciting applications of our novel sr39tk PET
reporter mouse are longitudinal cell tracking studies in the
context of health, disease and therapy. For example, tracking of
T lymphocytes on the whole-body level can improve our under-
standing of immune responses to infections and malignancies or
during immunotherapy. Diverse procedures have been developed
to label T cells in vitro for subsequent PET imaging in mice and
humans39–41. However, these experiments are often limited by
label dilution and artificial signal loss caused by the proliferation
of T cells in the course of an immune response42. In CD4/sr39tk
mice we were able, without the need for in vitro labeling, to follow
the homing of endogenous CD4+ T lymphocytes to sites of
TNCB-specific tissue inflammation over several weeks.
In another clinically relevant disease model, we used Myh6i/
sr39tk mice to monitor cardiomyocyte viability after MI. In both
preclinical and clinical studies, [18F]FDG is often used for this
purpose. However, [18F]FDG reports cellular glucose uptake and
metabolism, which are subject to complex regulation and
alterations under pathophysiological conditions such as ische-
mia43. Moreover, uptake of [18F]FDG is not cell-type specific. In
addition to cardiomyocytes, other cells in the myocardium may
accumulate [18F]FDG, in particular immune cells in the context
of post-infarct inflammation31, 32. For these reasons, detection of
sr39tk-labeled cardiomyocytes with [18F]FHBG appears to be a
more robust approach than [18F]FDG imaging, to specifically
assess cardiomyocyte viability in animal models of cardiac
disorders. Thus, we sought to use [18F]FHBG-PET for specific
detection of cardiomyocytes and [18F]FDG under conditions that
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favor its uptake into immune cells over cardiomyocytes for PET
imaging of post-infarct inflammation. Sr39tk or related PET
reporters have previously been expressed in rodent cardiomyo-
cytes using adenoviral approaches, but expression was limited to
the adenovirus-infected region and began to vanish some days
after virus administration17, 44, 45. In contrast, in Myh6i/sr39tk
mice we observed uniform and stable sr39tk expression in the
entire myocardium, which allowed longitudinal tracking of
cardiomyocyte viability in sub-regions of the heart after MI. The
spatial profile and relative amount of [18F]FHBG uptake after MI
induction remained constant over the whole 3-week period of our
study. The combination of PET imaging with [18F]FHBG
and [18F]FDG enabled us to characterize infarcts in detail by
visualization of viable cardiomyocytes and post-infarct inflam-
mation, respectively. The fact that permanent LAD ligation
results in almost complete loss of perfusion of the infarcted
zone might complicate the interpretation of tracer uptake in this
region after permanent LAD ligation. However, after I/R injury,
perfusion is maintained and thus it appears that the stable
reduction of [18F]FHBG uptake in the infarcted region was
indeed due to cardiomyocyte death rather than loss of perfusion.
In contrast, [18F]FDG uptake after I/R injury was initially
increased in the infarcted region and was more variable over time,
presumably due to inflammatory processes within the infarcted
region and [18F]FDG uptake into immune cells.
Taken together, this study demonstrates the suitability of our
novel sr39tk PET reporter mouse for non-invasive visualization,
quantification and tracking of specific cell populations in mice. The
binary nature of the system permits labeling of a broad spectrum of
cell types by crossbreeding the sr39tk reporter line with different
Cre strains, several hundreds of which are available for targeting
basically any cell type of interest (http://www.creportal.org). It is
also possible to combine the sr39tk PET reporter allele with other
Cre-switchable reporter transgenes. This enables, for instance,
combined in vivo imaging of cells by PET and other modalities
(e.g., fluorescence, bioluminescence) or validation of PET data by
post-mortem histochemical cell detection by X-Gal staining of
β-galactosidase activity. Moreover, combination of the sr39tk PET
reporter with Cre-sensitive conditional knockout alleles allows in
vivo-tracking of cell populations that lack a protein of interest.
Previous methods for cell tracking with PET were based on direct in
vitro-labeling of cells or transgenic expression of a PET reporter
protein under the control of a tissue-specific promoter. Our
Cre/lox-based PET reporter approach has one major advantage
over these methods, in that it permits in vivo labeling of essentially
any cell type of interest followed by stable/inheritable expression of
the PET reporter protein irrespective of cell phenotype and
potential silencing of a tissue-specific promoter. The latter property
might be particularly useful to keep track of initially labeled cells
after dedifferentiation or transdifferentiation, for instance, during
vascular remodeling46 or cell therapy3. If tamoxifen-inducible Cre
recombinases such as CreERT2 are used for cell labeling, it should
be considered that only cells will be labeled that expressed the
recombinase during the tamoxifen pulse and that these cells might
later be “diluted” by non-labeled cells originating from a pool of
CreERT2-negative progenitor cells. For instance, if in our MI model
newly formed cardiomyocytes were derived from sr39tk− pro-
genitor cells, then these cardiomyocytes would not take up
[18F]FHBG, and cell viability would be underestimated by [18F]
FHBG-PET. In general, labeling of rapidly proliferating cell popu-
lations with tamoxifen-inducible CreERT2 may be mosaic and,
therefore, non-recombined cells may dilute the reporter signal when
they proliferate. This problem can be addressed by using a non-
inducible Cre line, for instance, the Myh6-Cre line for efficient
labeling of cardiomyocytes.
We foresee many applications of our sr39tk PET reporter mice
in preclinical research. In combination with MRI or other PET
tracers (as shown in the present study), this mouse line will
improve our understanding of mammalian (patho-)biology
associated with migration, accumulation, death, or survival of
distinct cell populations. These processes are of fundamental
importance in clinical conditions such as inflammation, diabetes,
atherosclerosis, thrombosis, MI, stroke and tumorigenesis. Our
method will also be useful to elucidate endogenous mechanisms
of tissue degeneration and regeneration as well as effects of
therapeutic interventions. Cells derived from sr39tk PET reporter
ES cells or mice can aid the development of effective cell-based
therapies, which requires monitoring of the location, distribution
and long-term viability of the transplanted cells in a non-invasive
manner3, 4. In this context, sr39tk can be used not only as a PET
reporter, but also as a suicide gene enabling the elimination of
therapeutic cells by ganciclovir treatment, if they are causing
severe adverse effects47. We anticipate that the Cre-switchable
sr39tk PET reporter mice will be broadly applicable to address
complex biological questions in vivo and, compared to invasive
cell-tracking methods, enable preclinical research with fewer
animals and complementary informative value.
Methods
Experimental animals. All animal experiments were performed at the University of
Tübingen and approved by the local authority (Regierungspräsidium Tübingen, PC
1/08 and IB 1/13). Mice were housed in a barrier-free or individually-ventilated-cage
mouse facility at 19–22 °C and 40–60% humidity in a 12/12 h light/dark cycle with
free access to standard rodent chow and tap water. R26-mT/sr39tk PET reporter
mice (B6;129-Gt(ROSA)26Sortm2(ACTB-tdTomato,-sr39tkFeil)) were generated in this
study and had a mixed 129 Sv/C57BL6N genetic background. R26-lacZ Cre reporter
mice (B6.129-Gt(ROSA)26Sortm1Sor)10 were on a C57BL/6N background. Cre mice
were obtained from the following sources: CD4-Cre (Tg(Cd4-cre)1Cwi)23 from Ari
Waisman (University of Mainz, Mainz, Germany); Pf4-Cre (Tg(Cxcl4-cre)Q3Rsko/J)
22 and Myh6-Cre (Tg(Myh6-cre)2182Mds)24 from The Jackson Laboratories
(Bar Harbor, ME, USA); Myh6-CreERT2 (Tg(Myh6-icre/ERT2)Wet)30 from Andreas
Friebe (Universität Würzburg, Würzburg, Germany). All Cre lines were maintained
on a C57BL/6N background.
The generate experimental animals, male Cre[tg/+],R26[+/+] mice were mated
with female Cre[+/+],R26[sr39tk/+] mice; “+” denotes the wild-type allele. To
correlate [18F]FHBG accumulation with expression of β-galactosidase encoded by
the R26-lacZ Cre reporter10, male Cre[tg/+],R26[lacZ/+] mice were mated with
female Cre[+/+],R26[sr39tk/+] mice. Experimental animals were males and
females with an age between 9 and 42 weeks (for further details, see Supplementary
Table 1). The sr39tk-expressing mice (designated Cre/sr39tk or sr39tk+) had the
genotype Cre[tg/+],R26[sr39tk/+]; animals that expressed sr39tk and
β-galactosidase (designated Cre/sr39tk+ lacZ) had the genotype Cre[tg/+],
R26[sr39tk/lacZ]; Cre-negative control animals that did not express sr39tk
(designated sr39tk−) or lacZ (designated lacZ−) had the genotype Cre[+/+],
R26[sr39tk/+] or Cre[+/+],R26[sr39tk/lacZ]. In addition, Cre[tg/+] mice were
mated with R26[lacZ/+] mice to generate β-galactosidase-expressing animals
(designated Cre/lacZ; genotype: Cre[tg/+],R26[lacZ/+]) and respective Cre-
negative control animals (genotype: Cre[+/+],R26[lacZ/+]).
Generation of R26-mT/sr39tk mice. The gene targeting vector
pRosa26-mT/sr39tk was used to integrate the CAG promoter, a loxP-flanked
expression cassette for membrane-targeted tandem-dimer red fluorescent protein
(mT), and the sr39tk encoding sequence followed by a FRT-flanked neomycin-
resistance cassette into the murine R26 locus (Supplementary Fig. 1a). To generate
pRosa26-mT/sr39tk, the coding sequence of membrane-targeted green fluorescent
protein (mG) in pRosa26-mT/mG18 (Addgene plasmid 17787) was replaced by the
sr39tk-encoding sequence15 isolated from pCMV-sr39tk (provided by Sam
Gambhir, Stanford University, CA, USA). Gene targeting was performed as
described19, 48. In brief, 60 µg of AclI-linearized pRosa26-mT/sr39tk were elec-
troporated into R1 ES cells49. After 8 days of selection with 320 µg mL−1 G418
(GIBCO, Life Technologies, Darmstadt, Germany), 200 clones were isolated and
expanded. Fourteen correctly targeted ES cell clones carrying the R26-mT/sr39tk
knock-in allele were identified by Southern blot analysis of EcoRV-digested
genomic DNA with a probe that binds 5′ to the integration site50. R26-mT/sr39tk
mice were generated by injection of ES cells into 3.5 dpc C57BL/6N blastocysts.
Male chimeras were mated with C57BL/6N females to obtain heterozygous
R26-mT/sr39tk mice (B6;129-Gt(ROSA)26Sortm2(ACTB-tdTomato,-sr39tk)Feil) on a
mixed 129 Sv/C57BL6N genetic background. Germline transmission of the mod-
ified R26 allele was verified by Southern blot analysis of tail DNA. Heterozygous
male R26-mT/sr39tk mice showed a severely reduced reproductive rate
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(no offspring from >10 different heterozygous R26-mT/sr39tk males). Hetero-
zygous female R26-mT/sr39tk mice were fertile and were backcrossed to C57BL/6N
animals for three to eight times before experimental animals were generated.
Genotyping. PCR-based genotyping of ear biopsies was done for R26-mT/sr39tk
mice with primers ROSA10 (5′-CTCTGCTGCCTCCTGGCTTCT-3′), ROSA11
(5′-CGAGGCGGATCACAAGCAATA-3′) and ROSA04 (5′-TCAATGGGCGGG
GGTCGTT-3′)51 (Supplementary Fig. 1a), and for R26-lacZ mice with ROSA10,
ROSA11 and RF127 (5′-GCGAAGAGTTTGTCCTCAACC-3′)10. ROSA10 and
ROSA11 amplify a 330-bp fragment of the wild-type R26 locus, ROSA10 and
ROSA04 amplify a 250-bp fragment of the R26-mT/sr39tk allele, and ROSA10 and
RF127 amplify a ca. 200-bp fragment of the R26-lacZ allele. Mice potentially
carrying both R26-mT/sr39tk and R26-lacZ alleles were genotyped with a four-
primer PCR containing ROSA10, ROSA11, ROSA4 and RF127.
Routine genotyping of CD4-Cre and Myh6-Cre lines was performed with
primers Cre800 (5′-GCTGCCACGACCAAGTGACAGCAATG-3′) and Cre1200
(5′—GTAGTTATTCGGATCATCAGCTACAC-3′), which amplify a 400-bp
fragment of the Cre transgene. To detect the Pf4-Cre and Myh6-CreERT2
transgenes, we used primers EiCre1 (5′-GACAGGCAGGCCTTCTCTGAA-3′) and
EiCre2 (5′-CTTCTCCACACCAGCTGTGGA-3′), which amplify a 522-bp
fragment52. Verification of Cre lines was performed with PCR primers specific for
the Cre transgene as described in the respective original publications22–24, 30.
Generation and analysis of ES cells with activated sr39tk expression.
R26-mT/sr39tk ES cells carrying the Cre-activatable L2 allele were electroporated
with the Cre-expression plasmid pIC-Cre53 to generate ES cells with an excised mT
cassette and activated sr39tk expression (L1 allele) (Supplementary Fig. 1a). ES cell
clones carrying the L1 allele were identified by a combination of Southern blot
analysis, fluorescence microscopy to detect loss of mT expression and growth
assays to test their sensitivity to the sr39tk suicide substrate ganciclovir (see below).
Out of 96 clones analyzed, 12 showed the expected DNA fragment pattern, loss of
mT fluorescence and growth inhibition in the presence of ganciclovir. For further
analyses, selected R26-mT/sr39tk (+/L2) and Cre-recombined (+/L1) ES cell clones
were thawed and expanded from frozen replica plates.
For western blot analysis, ES cell extracts were prepared in SDS lysis buffer (2%
SDS, 50 mM Tris-Cl pH 8.0, 5 mM EDTA, 100 mM NaCl). Protein content of cell
extracts was measured with the Total Protein Kit, Micro Lowry, Peterson’s
modification (Sigma-Aldrich, Darmstadt, Germany). Cell lysates containing 20 µg
protein were subjected to SDS-PAGE and western blot analysis on polyvinylidene
fluoride membranes. Membranes were stained with a polyclonal rabbit HSV1-tk
antiserum (1:2,000) provided by William C. Summers (Yale University, CT, USA)
and horseradish-peroxidase-coupled goat anti-rabbit secondary antibody (1:5,000,
Cell Signaling, Danvers, MA, USA). To confirm equal protein loading, a second gel
run with the same samples was stained with Coomassie Brilliant Blue according to
standard procedures.
For cell growth assays, ES cells were seeded into six-well plates with feeder cells
and incubated in ES cell medium consisting of Dulbecco’s modified Eagle’s
medium supplemented with 20% fetal calf serum (FCS) (GIBCO), 0.1 mM
2-mercaptoethanol and 1,000 UmL−1 leukemia-inhibitory factor (ESGRO,
Millipore, Darmstadt, Germany) at 37 °C and 5% CO2. After 24 h, medium was
changed to ES cell medium with or without 2 µM ganciclovir (Roche, Mannheim,
Germany). Medium was changed every 1–2 days. Cell growth was documented
with a digital camera attached to a phase contrast microscope (Axiovert 40, Zeiss,
Jena, Germany).
For analysis of [18F]FHBG uptake into ES cells in culture, cells were seeded into
six-well plates on feeder cells 4 days before the experiment. On the day of the
experiment, medium was exchanged with 3 mL ES cell medium containing
740 kBq mL−1 (20 µCi mL−1) [18F]FHBG and cells were further incubated at 37°C
and 5% CO2. After 30, 60 and 120 min, the supernatants were collected and cells
were washed twice with 1 mL phosphate-buffered saline (PBS); pooled supernatant
and PBS washes of each well represented the extracellular fraction. For each time
point, three replicates were prepared. Then, cells were lysed directly in the wells
with 1 mL SDS lysis buffer (2% SDS, 50 mM Tris-Cl pH 8.0, 5 mM EDTA, 100 mM
NaCl) per well. Cell lysates were collected and wells were washed twice with 2 mL
PBS; pooled lysate and PBS washes of each well represented the intracellular
fraction. Radioactivity was measured in a γ-counter (Wallac 1470 WIZARD, Perkin
Elmer, Turku, Finland) and intracellular [18F]FHBG accumulation was calculated
as ratio of intracellular fraction to total radioactivity measured in the intracellular
and extracellular fraction.
Flow cytometry and platelet count. Single cell suspensions of spleen, lymph
nodes and thymus were obtained via 70-µm cell strainers in fluorescence-activated
cell sorting (FACS) buffer (PBS containing 5% FCS). After lysis of red blood cells
with ACK lysis buffer, cells were separated via 40-µm cell strainers and stained with
flurochrome-conjugated antibodies (V500-coupled anti-CD45.2, V450-coupled
anti-CD4, fluorescein isothiocyanate-coupled anti-CD8 (BD Biosciences, Heidel-
berg, Germany); APC-coupled anti-CD3 (Biolegend)) for 30 min at 4 °C in FACS
buffer. Flow cytometry was performed using a BD LSR II Flow Cytometer (BD
Biosciences) and analyzed with FlowJo software (FlowJo, Ashland, OR, USA).
Platelet counts were determined in whole blood drawn from the retroorbital
plexus of isoflurane-anesthetized animals into 300 μL acid citrate-dextrose buffer.
Platelet numbers were determined with an automated blood analyzer (Sysmex Se
9000, Kobe, Japan).
Cutaneous DTHR model. Delayed-type hypersensitivity reactions (DTHRs) were
induced with 2,4,6-trinitrochlorbenzene (TNCB) as described previously29. Briefly,
mice were sensitized by application of 80 μL of 5% TNCB dissolved in a 4:1 mixture
of acetone and Miglyol 812 (SASOL, Witten, Germany) to the shaved abdomen.
Seven, 10 and 12 days later, mice were challenged with
20 μL of 1% TNCB dissolved in a 1 : 9 mixture of acetone and Miglyol 812 on both
sides of the left ear to elicit a TNCB-specific contact hypersensitivity reaction. The
degree of inflammation was assessed through measurement of ear thickness with a
digital micrometer before the first TNCB challenge, 12 h after each subsequent ear
challenge, and then every 3 days.
MI model. MI was performed by surgical ligation of the LAD coronary artery. Briefly,
mice were anesthetized with 5mg kg−1 midazolam, 0.5mg kg−1 medetomidin and
0.05mg kg−1 fentanyl. After oro-tracheal intubation and ventilation, the thoracic
cavity was surgically exposed. For permanent ligation, the LAD was ligated with a
non-resorbable 8-0 filament. I/R injury was induced by ligation of the LAD for 60min
with the aid of a polyethylene tube. Ischemia and reperfusion were confirmed by
discoloration and akinesia or recoloration, respectively, of the ischemic region. Sham
treatment was performed without ligation of the filament. After closing of the access
site, anaesthesia was antagonized by injection of atipamezol (2.5mg kg−1) and flu-
mazenil (0.5mg kg−1), and animals were monitored until recovery. Buprenorphine
(0.05mg kg−1) was injected subcutanously for analgesia.
PET tracer synthesis. Tracers were synthetized by the Department of Preclinical
Imaging and Radiopharmacy, Werner Siemens Imaging Center Tübingen.
[18F]Fluoride was produced at the PETtrace cyclotron (General Electric Healthcare,
Uppsala, Sweden) using [18O]water (Rotem, Leipzig, Germany) and the 18O(p,n)18F
nuclear reaction. [18F]FHBG was synthetized according to previously described
procedures54 with some modifications. [18F]Fluoride was transferred to an auto-
mated synthesis module (TRACERlab FX-FN, GE Healthcare, Liège, Belgium) and
first adsorbed on an ion exchange cartridge (SEP-PAK light, Accell Plus QMA,
Waters, USA) preconditioned with 10ml of 1 N aqueous NaHCO3 and 10mL
water. [18F]Fluoride was eluted and flushed into the reaction vial with a mixture of
900 μL of acetonitrile and 100 µL of water wherein 3.5 mg (25 µmol) of K2CO3 and
15 mg (40 µmol) Kryptofix 2.2.2. were dissolved. The solution was dried under
vacuum at 60 °C for 5 min and afterwards at 120 °C for additional 5 min. Labeling
was carried out using 4 mg of the precursor Tosyl-FHBG (ABX, Radeberg,
Germany) in 1 mL dimethyl sulfoxide under stirring at 120 °C within 5 min.
Hydrolysis was achieved with 1 mL of 1 N HCl at 100 °C in 5 min. For
neutralization of the reaction mixture, 0.4 mL of 2 N aqueous NaOH was added.
Unreacted [18F]fluoride was removed by passing the reaction solution through an
Al2O3-cartridge (SEP-PAK light, Alumina N, Waters) preconditioned with 10mL
water. Afterwards, the reactor was flushed with 0.5 mL of water, which was also
passed through the Al2O3 cartridge. The combined fractions were injected onto the
high-performance liquid chromatography (HPLC) column (Phenomenex Luna
column C18/2, 250 × 10mm; 5 µm) for separation. A mixture of ethanol/50 mM
Na2HPO4 (5/95, v/v) was used as eluent. Retention time of the product was
18–22min at a flow rate of 4 mLmin−1, detected by UV (254 nm) and radio
detector. The pH was adjusted to 7.4–7.6 by adding 0.25 mL of 0.4 N NaH2PO4.
Finally, the product was sterile filtered through a 0.22-µm filter. Overall synthesis
time was 60min. Volume of the product was in the range of 6–10mL, activity of the
batches was 1.9–3.9 GBq. Radiochemical purity was determined via thin layer
chromatography/phosphor imager analysis and HPLC and was 82–92% with both
methods. Specific activity was >100 GBq µmol−1 at the end of synthesis. [18F]FDG
was synthesized in a TRACERlab MXFDG synthesizer (GE Healthcare) using
previously established methods55 and mannose triflate (ABX) as a precursor.
Quality control was performed in accordance with European pharmacopoeia quality
guidelines. The radiochemical purity as determined by thin layer
chromatography was >95%.
In vivo PET imaging and ex vivo analysis of tracer uptake. Animals were
imaged using dedicated Inveon small animal PET scanners (Siemens Preclinical
Solutions, Knoxville, TN, USA) yielding a spatial resolution of ≈1.3mm in the
reconstructed images56. For [18F]FHBG imaging, animals were anesthetized for
5–10min with 1.5% isoflurane in pure oxygen and injected with tracer into the
tail vein., and 180 min after tracer injection for conscious uptake, animals were
anesthetized with 1.5% isoflurane in pure oxygen and PET acquisition was
performed for 20min. For [18F]FDG imaging, ketamine (100mg per kg body
weight) and xylaxine (10mg per kg body weight) were used for anesthesia. Sixty
minutes after tracer injection into the tail vein and unconscious uptake on a heating
blanket, a 10min PET acquisition was performed. All PET data were reconstructed
with an iterative ordered-subset expectation maximization algorithm.
MR imaging was performed on dedicated 7T small animal MR tomographs
(Bruker Biospin MRI and ClinScan, Bruker, Ettlingen, Germany) with fiducial
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markers containing 18F activity for subsequent image fusion. A T2-weighted three-
dimensional space sequence (TE/TR 205/3000 ms, matrix of 161 × 256, slice
thickness 0.22 mm) was used to obtain morphological information.
For data analysis, PET and MRI images were fused, normalized to each other and
analyzed using Inveon Research Workplace software (Siemens Preclinical Solutions)
or Amide57. To analyze tracer uptake into selected organs, three-dimensional regions
of interest (ROIs) were manually defined. When available, co-registered MR images
were used to define ROIs; otherwise, PET tracer uptake patterns were used for ROI
definition. To analyze regional uptake into the myocardium, 17-segment PMs58 of
cardiac PET images were created using PMOD software (PMOD Technologies Ltd,
Zurich, Switzerland). Uptake of [18F]FHBG and [18F]FDG are reported as percent
injected dose (ID) per cubic centimeter (%ID/c.c.m.).
To determine [18F]FHBG uptake in isolated organs and tissue slices, animals were
killed and dissected tissues were subjected to biodistribution analysis or
autoradiography. To analyze tracer biodistribution, organ radioactivity was measured
in a γ-counter (Wallac 1470 WIZARD). The fraction of injected tracer dose per gram
tissue (%ID per g) was calculated by normalizing decay-corrected counts to ID and
sample wet weight. For autoradiography, organs were embedded and snap-frozen in
O.C.T. TissueTek Compound (Sakura Finetek, Torrance, CA, USA). Organs were cut
into 20-μm sections using a CM1850 cryostat (Leica Microsystems, Wetzlar,
Germany). Dry sections were placed on a phosphor screen. After 24 h, the screen was
read using a STORM Phosphor-Imager (Molecular Dynamics, Sunnyvale, CA, USA).
Then, sections were stained with hematoxylin and eosin. Tissue sections from mice
carrying also the R26-lacZ reporter gene were stained with X-Gal as described below.
Stained sections were visually examined (Axioskop, Zeiss) or scanned with a
NanoZoomer 2.0-HT C9600 (Hamamatsu Photonics, Herrsching am Ammersee,
Germany). Analysis of autoradiographs and photomicrographs was performed with
ImageJ (National Institute of Health, Bethesda, MD, USA).
X-Gal staining and immunohistochemistry. X-Gal staining of whole-mount
organs was performed as described9. Animals were transcardially perfused with
Heparin-PBS (PBS with 250 mg L−1 heparin) followed by PBS containing 2%
formaldehyde and 0.2% glutaraldehyde. After dissection, organs were fixed for 1 h
in the same fixative solution at room temperature, washed twice with PBS, and
incubated overnight at room temperature in X-Gal staining solution (PBS at pH 7.4
containing 2.5 mM K3Fe(CN)6, 2.5 mM K4Fe(CN)6, 2 mM MgCl2, 1 mg mL−1
X-Gal). After staining, tissues were washed with PBS and stored at 4 °C in 70%
ethanol. Documentation was performed with a digital camera attached to a stereo
microscope (Stemi 2000, Zeiss).
X-Gal staining of blood was performed with samples drawn from the heart into
Heparin-PBS. They were mixed with an equal volume of PBS containing 2%
formaldehyde and 0.2% glutaraldehyde, and fixed for 15 min at room temperature.
Then, samples were centrifuged at 200 g for 5 min, washed three times with PBS
and incubated overnight at room temperature in X-Gal staining solution. Stained
blood cells were washed three times with PBS, mixed 1:1 with aqueous mounting
medium (Aquatex, Merck, Darmstadt, Germany) and examined on a bright field
microscope (Axiovert 40, Zeiss).
For X-Gal staining of tissue sections, mice were transcardially perfused with
Heparin-PBS followed by PBS containing 0.2% glutaraldehyde. After dissection,
organs were removed and left for another hour in PBS with 0.2% glutaraldehyde at
room temperature. After three washes with PBS, organs were kept in 30% sucrose
overnight at 4 °C. Organs were embedded in O.C.T. TissueTek Compound (Sakura
Finetek), snap-frozen and cut at −25 °C into sections of 10 or 20 µm thickness.
Sections were mounted on SuperFrost Plus glass slides (Thermo Fisher,
Braunschweig, Germany), dried at room temperature, incubated for 10 min in PBS
containing 0.2% glutaraldehyde and 2 mM MgCl2 at 4 °C, followed by three washes
with PBS containing 0.1% Triton X-100 and 2 mM MgCl2 at room temperature.
Staining was performed overnight in X-Gal staining solution at room temperature.
After three washes with PBS containing 0.1% Triton X-100 and 2 mM MgCl2,
sections were incubated in PBS with 4% formaldehyde for 10 min and washed
again with PBS containing 0.1% Triton X-100 and 2 mM MgCl2. Then, sections
were counterstained with hematoxylin/eosin or nuclear fast red, dehydrated and
mounted with DePeX (Merck). Embedded sections were examined on a light
microscope (Axiovert 40, Zeiss) or scanned with a NanoZoomer 2.0-HT C9600
(Hamamatsu Photonics).
Immunohistochemistry was performed on 3–5-µm-thick paraffin sections
stained with antibodies against CD31 (Abcam, Cambridge, UK) or Mac3
(BD Biosciences). Immunohistochemistry was performed on an automated
immunostainer (Ventana Medical Systems, Oro Valley, AZ, USA) according to the
company’s protocols for open procedures with slight modifications. Sections were
counterstained with hematoxylin. Appropriate positive and negative controls were
used to confirm specificity of staining.
Data analysis and statistical methods. Investigators were not blinded for
genotype or treatment of the animals during experiments and data evaluation.
Sample sizes were chosen as minimal requirement to faithfully detect in vivo
functionality of the R26-mT/sr39tk PET reporter approach (typically three to six
animals per group). Statistical analyses were performed with Microcal Origin (Pro
2016; OriginLab Corporation, Northampton, MA). One-way analysis of variance
was used to compare groups as detailed in the figure legends, where *p < 0.05,
**p< 0.01 and ***p < 0.001, respectively. Normal distribution of data was not
tested. Homogeneity of variance between groups was tested using the
Brown–Forsythe test.
Data availability. All relevant data are available upon request from the
corresponding author.
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